Healthcare
Evommune, Inc.(EVMN)
Live Price
Offline$22.55
+5.57% today
Window Change
+11.47%
Window
Nov 6, 2025 โ Jun 22, 2026
- Market Cap
- $310.00M
- Revenue Growth
- +85.7%
- EPS Growth
- +4.0%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 154 bars ยท Nov 6, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Evommune, Inc. (EVMN) is a Healthcare stock with a market cap of $310.00M and listed on NYSE. The stock last traded around $22.55 and up 11.5% across the available one-year price window (Nov 6, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +85.7%, EPS growth of +4.0%, a dividend yield of 0.0%. What stands out right now is revenue +85.7%, EPS +4.0%, free cash flow -31.6% with operating margin -623.6% and ROIC -39.0%. Valuation already assumes a fairly strong business story at price/sales 23.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines EVMN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+85.7% vs +7.6% peer median
Operating Margin
Below sector median
-623.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +85.7% and EPS at +4.0%, with operating margin around -623.6%.
The next real check-in already has a date
The next earnings event is scheduled for Oct 16, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 4, 2026 | โ | -3.7% | +0.0% | โ |
2026 Mar 5, 2026 | -74.4% | +5.6% | -8.4% | -5.5% |
2025 Dec 11, 2025 | -32.7% | -8.5% | -23.8% | +6.3% |
Benchmark Edge
EVMN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EVMN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EVMN Max Drawdown
-37.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EVMN and SPY.
Company Overview
Evommune, Inc.
New York Stock Exchange
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
- Leadership
- Luis C. Pena
- IPO Date
- Nov 6, 2025
- Employees
- 45
- Street Address
- 1841 Page Mill Road
- Mailing
- Palo Alto, CA, 94304
- Region
- Palo Alto, CA, US
- Reporting Currency
- USD
- Investor Line
- (925) 247-4487
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 23.9
- Price/Book
- 3.7
Growth
- Revenue
- +85.7%
- EPS
- +4.0%
- Free Cash Flow
- -31.6%
Profitability
- Gross Margin
- 89.3%
- Operating Margin
- -623.6%
- Net Margin
- -529.8%
- ROE
- 89.7%
- ROIC
- -39.0%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 8.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.